ROCKVILLE, Md., Aug. 26, 2014 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing
novel anti-infective biologic and drug programs targeting specific
pathogens that cause serious infections and diseases, announced
today that SYN-004, the Company's lead anti-infective product
candidate for the prevention of the devastating effects of
Clostridium difficile (C. difficile), will be presented at
the Infectious Disease Week (IDWeek 2014™) held by the
Infectious Diseases Society of America (IDSA), October 8-12, in Philadelphia, PA.
Synthetic Biologics' Senior Vice President, Research &
Development, Mike Kaleko M.D.,
Ph.D., will present a poster outlining preclinical data supporting
the development of SYN-004 as a prophylactic against C.
difficile. SYN-004 is designed to protect the
gastrointestinal (GI) microflora – or gut microbiome – from the
effects of certain commonly used intravenous (IV) antibiotics,
thereby preventing C. difficile infection. The U.S. Centers
for Disease Control and Prevention (CDC) has classified C.
difficile as an "urgent public health threat", ranking it as
the number one hospital-acquired infection in the United States.
The SYN-004 poster will be available for viewing in Exhibit Hall
BC at the Pennsylvania Convention
Center on Thursday, October 9, from
12:30pm to 2:00pm Eastern Time, as
part of the "Antimicrobial Resistance: Novel Agents and
Approaches to Gram-Positive Infections" session.
Title: SYN-004, a Class A Beta-Lactamase Therapy for the
Prevention of Antibiotic-Induced Disruption of Intestinal
Microflora
Authors1: Michael Kaleko, J.
Andrew Bristol, Sheila
Connelly, Pertti Koski,
PhD
Presentation Number: 270
"We are pleased SYN-004 for the prevention of C.
difficile continues to gain visibility and recognition among
our academic peers as it advances toward the clinic," noted
Jeffrey Riley, Chief Executive
Officer of Synthetic Biologics. "We are on schedule to initiate
Phase Ia and Phase Ib trials of SYN-004 this year, followed by a
planned Phase II efficacy trial in the first half of next
year."
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology
company focused on the development of novel anti-infective biologic
and drug candidates targeting specific pathogens that cause serious
infections and diseases. The Company is developing an oral biologic
to protect the gastrointestinal microflora from the effects of IV
antibiotics for the prevention of Clostridium difficile (C.
difficile) infection, an oral treatment to reduce the impact of
methane producing organisms on constipation-predominant irritable
bowel syndrome (C-IBS), a series of monoclonal antibodies for the
treatment of Pertussis and Acinetobacter infections, and a
biologic targeted at the prevention and treatment of a root cause
of a subset of IBS. In addition, the Company is developing an oral
estriol drug for the treatment of relapsing-remitting multiple
sclerosis (MS) and cognitive dysfunction in MS. For more
information, please visit Synthetic Biologics' website at
www.syntheticbiologics.com.
1Synthetic Biologics, Rockville, MD
This release includes forward-looking statements on Synthetic
Biologics' current expectations and projections about future
events. In some cases forward-looking statements can be identified
by terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions. These statements are based
upon current beliefs, expectations and assumptions and are subject
to a number of risks and uncertainties, many of which are difficult
to predict and include statements regarding Synthetic Biologics'
continued advancement of its C. difficile program toward clinical
trials and the planned trials. The forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially from those set forth or implied by any
forward-looking statements. Important factors that could cause
actual results to differ materially from those reflected in
Synthetic Biologics' forward-looking statements include, among
others, the additional clinical studies and results not meeting
expectations and other factors described in Synthetic Biologics'
report on Form 10-K for the year ended December 31, 2013 and any other filings with the
SEC. The information in this release is provided only as of the
date of this release, and Synthetic Biologics undertakes no
obligation to update any forward-looking statements contained in
this release on account of new information, future events, or
otherwise, except as required by law.
Logo -
http://photos.prnewswire.com/prnh/20130522/MM19465LOGO
SOURCE Synthetic Biologics, Inc.